eFFECTOR Secures $50M Funding From Lincoln Park Capital

eFFECTOR Therapeutics Inc EFTR entered into an investment agreement with Lincoln Park Capital for up to $50 million over 36 months.

• The Company said a new group was added to evaluate frontline maintenance in patients with PD-L1 ≥1% in the Phase 2b KICKSTART trial of tomivosertib combined with Merck & Co Inc's MRK Keytruda (pembrolizumab) for non-small cell lung cancer (NSCLC).
• This cohort will enroll approximately 60 patients.
• Topline data from the ongoing frontline cohort in patients with PD-L1>50% and the new frontline maintenance cohort in patients with PD-L1>1% in the KICKSTART trial are now expected in H1 2023.
• eFFECTOR also said it was discontinuing the development of tomivosertib in patients who have already progressed on pembrolizumab monotherapy.
• In addition, first patients have been dosed in two additional Phase 2 expansion cohorts evaluating zotatifin in combination with sotorasib in KRAS G12C-mutant NSCLC and combination with abemaciclib and fulvestrant in ER+/HER2- breast cancer.
• Related: eFFECTOR Therapeutics Stock Gains On Encouraging Preclinical Zotatifin Data In Breast Cancer.
• eFFECTOR anticipates initial response data from one or more of the expansion cohorts, and additional data from the Phase 1 dose-escalation portion of the trial, in 1H of 2022. 
• It anticipates topline results from the trial in 2H of 2022.
• Price Action: EFTR shares closed 4.21% lower at $6.04 during after-hours trading on Monday.